brexucabtagene autoleucel
gilead
['zuma-3', 'leusm', 'tecartus']
#asco23 #leusm faramand: rocca (rwe consortium for tecartus outcomes) study is important, because pts who wouldn t have been eligible for zuma-3 are now receiving this product. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)